Pharmaceutical companies are altering or selectively reporting clinical trial outcomes to secure approvals or boost investor confidence.

The claim that pharmaceutical companies alter or selectively report clinical trial outcomes to secure approvals or boost investor confidence is partially supported by evidence. Studies have shown that a significant portion of clinical trial results are not publicly disclosed, with only 25% of large pharmaceutical companies fully meeting data sharing measures, and many trials not reporting results on time or at all BMJ Science. Additionally, there is evidence of reporting bias, where trials with positive outcomes are more likely to be published, potentially skewing the perception of a drug's efficacy Pharmaceutical Journal.